Acenocoumarol

Known as: 3-(alpha-Acetonyl-P-nitrobenzyl)-4-hydroxycoumarin, Acenocoumarol [Chemical/Ingredient], Nitrophenylacetylethyl-4-hydroxycoumarine 
A 4-hydroxycoumarin derivative with anticoagulant activity. As a vitamin K antagonist, acenocoumarol inhibits vitamin K epoxide reductase, thereby… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

1956-2017
02040608019562016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2013
Highly Cited
2013
BACKGROUND Standard treatment for venous thromboembolism (VTE) consists of a heparin combined with vitamin K antagonists. Direct… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
OBJECTIVES The objective of this study was to compare the predictive performance of bleeding risk-estimation tools in a cohort of… (More)
  • table 1
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2010
Highly Cited
2010
BACKGROUND Rivaroxaban, an oral factor Xa inhibitor, may provide a simple, fixed-dose regimen for treating acute deep-vein… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?
Highly Cited
2009
Highly Cited
2009
Several genome-wide association studies have been performed on warfarin. For acenocoumarol, the most frequently used coumarin in… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
Highly Cited
2005
Highly Cited
2005
The aim of the study is to explore the contribution of genetic factors related either to drug metabolism (cytochrome P450 2C9) or… (More)
  • table 1
  • figure 1
  • table 2
  • table 3
  • table 4
Is this relevant?
2004
2004
OBJECTIVE The aim of this study was to investigate the respective contribution of the different cytochrome P450 (CYP) 2C9 genetic… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVES This trial evaluated the efficacy and safety of the combination of antiplatelet and moderate-intensity anticoagulation… (More)
Is this relevant?
Highly Cited
2001
Highly Cited
2001
BACKGROUND In patients with idiopathic deep venous thrombosis, continuing anticoagulant therapy beyond three months is associated… (More)
Is this relevant?
Highly Cited
1993
Highly Cited
1993
BACKGROUND Insufficient data are available about the safety of oral anticoagulant therapy. The specialized organization of… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • table 5
Is this relevant?
Highly Cited
1992
Highly Cited
1992
BACKGROUND In most countries, heparin is used in the initial treatment of patients with deep-vein thrombosis. Well-designed… (More)
Is this relevant?